Toxicity related with brolucizumab

Abstract Introduction: Post-marketing studies identified severe vision-threatening side effects of brolucizumab, including retinal vasculitis (RV) and intraocular inflammation (IOI). Objective: To present the prevalence of IOI related to brolucizumab in our department, including the first reported case of an occlusive RV with retinal vascular occlusion (RO) and severe vision loss related to brolucizumab in Portugal. Results: There were 4 eyes with unilateral IOI related to brolucizumab (3.42%), one (0.85%) presenting uveitis, two (1.71%) vitritis and the last one presenting occlusive RV (0.85%), from a total of 117 eyes that were on brolucizumab therapy. Conclusion: although serious complications from brolucizumab therapy may appear to be rare, they may be distressful for the patient and the ophthalmologist since some of them may lead to irreversible blindness. Moreover, continuous report of serious sight-threatening events is mandatory, since continuous surveillance and evaluation from the regulatory authorities is needed, as it involves health and legal issues.